COVID-19 and the Functionality of Antivirals: The Day After Tomorrow.

Health Secur

Amin Sharifan, PharmD, is a Pharmacist and Researcher, Department of Pharmaceutical Care, Sina Hospital, and Research Center for Rational Use of Drugs; both at the Tehran University of Medical Sciences, Tehran, Iran.

Published: June 2022


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://dx.doi.org/10.1089/hs.2022.0073DOI Listing

Publication Analysis

Top Keywords

covid-19 functionality
4
functionality antivirals
4
antivirals day
4
day tomorrow
4
covid-19
1
antivirals
1
day
1
tomorrow
1

Similar Publications

Background: The COVID-19 pandemic forced the world to quarantine to slow the rate of transmission, causing communities to transition into virtual spaces. Asian American and Pacific Islander communities faced the additional challenge of discrimination that stemmed from racist and xenophobic rhetoric in the media. Limited data exist on technology use among Asian American and Pacific Islander adults during the height of the COVID-19 shelter-in-place period and its effect on their physical and mental health.

View Article and Find Full Text PDF

The COVID-19 pandemic, caused by the continuously evolving SARS-CoV-2 virus, has presented persistent global health challenges. As novel variants emerge, many with enhanced transmissibility and immune evasion capabilities, concerns have intensified regarding the efficacy of existing vaccines and therapeutics. This review provides a comprehensive overview of the current landscape of COVID-19 vaccination, including the development and performance of monovalent and bivalent boosters, and examines their effectiveness against newly emerging variants of interest (VOIs) and variants under monitoring (VUMs), such as JN.

View Article and Find Full Text PDF

Unrelated pathogens, including viruses and bacteria, use a common short linear motif (SLiM) to interact with cellular kinases of the RSK (p90 S6 ribosomal kinase) family. Such a "DDVF" (D/E-D/E-V-F) SLiM occurs in the leader (L) protein encoded by picornaviruses of the genus , including Theiler's murine encephalomyelitis virus (TMEV), Boone cardiovirus (BCV), and Encephalomyocarditis virus (EMCV). The L-RSK complex is targeted to the nuclear pore, where RSK triggers FG-nucleoporins hyperphosphorylation, thereby causing nucleocytoplasmic trafficking disruption.

View Article and Find Full Text PDF

Aim     To determine the prevalence and predictors for the development of newly diagnosed chronic heart failure (CHF) in patients with shortness of breath in long-term post-COVID syndrome.Material and methods            This screening cross-sectional clinical study was performed from April 2020 through April 2024, in two stages in an outpatient setting. At the first stage, 878 patients with shortness of breath were screened three or more months after COVID-19, and the presence of at least three diagnostic criteria for CHF, that were not in their history, was verified.

View Article and Find Full Text PDF

Introduction: Anti-N-methyl-D-aspartate receptor (NMDA-R) encephalitis is a neuropsychiatric disorder with additional psychiatric features caused by NMDA-R immunoglobulin G (IgG) antibodies in cerebrospinal fluid (CSF). This report presents the follow-up of a patient in whom we assumed mild NMDA-R encephalitis in the first psychotic episode.

Case Study: A patient with a prior episode of an acute polymorphic psychotic syndrome relapsed five and a half years later following a severe COVID-19 infection.

View Article and Find Full Text PDF